Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study

被引：8

作者：

Mordant, Pierre ^{[1
,21
]}

Brosseau, Solenn ^{[2
]}

Milleron, Bernard ^{[2
,3
]}

Santelmo, Nicola ^{[4
]}

Fraboulet-Moreau, Severine ^{[5
]}

Besse, Benjamin ^{[6
,7
]}

Langlais, Alexandra ^{[8
]}

Gossot, Dominique ^{[9
]}

Thomas, Pascal-Alexandre ^{[10
]}

Pujol, Jean-Louis ^{[11
]}

Ricordel, Charles ^{[12
,13
]}

Madelaine, Jeannick ^{[14
]}

Lamy, Regine ^{[15
]}

Audigier-Valette, Clarisse ^{[16
]}

Missy, Pascale ^{[8
]}

Blons, Helene ^{[17
]}

Barlesi, Fabrice ^{[18
]}

Westeel, Virginie ^{[19
,20
]}

机构：

[1] Assistance Publ Hop Paris, Bichat Claude Bernard Hosp, Dept Thorac Surg, Paris, France

[2] Assistance Publ Hop Paris, Bichat Claude Bernard Hosp, Dept Thorac Oncol, Paris, France

[3] Assistance Publ Hop Paris, Tenon Hosp, Dept Pneumol, Paris, France

[4] Rhena Private Hosp, Dept Thorac Surg, Strasbourg, France

[5] Foch Hosp, Dept Pneumol, Suresnes, France

[6] Gustave Roussy, Dept Canc Med, Villejuif, France

[7] Paris Saclay Univ, Orsay, France

[8] French Cooperat Thorac Intergrp, Paris, France

[9] Inst Mutualiste Montsouris, Inst Thorax Curie, Dept Thorac Surg, Paris, France

[10] Marseille Univ Hosp, Dept Thorac Surg, Marseille, France

[11] Montpellier Acad Hosp, Hop Arnaud Villeneuve, Thorac Oncol Unit, Montpellier, France

[12] CHU Rennes, Resp Med Dept, Rennes, France

[13] CLCC Eugene Marquis, INSERM U1242, Chem Oncogenesis Stress & Signaling, Rennes, France

[14] Caen Normandie Univ Hosp, Dept Thorac Oncol, Caen, France

[15] Grp Hosp Bretagne Sud, Scorff Hosp, Dept Oncol, Lorient, France

[16] Toulon Sainte Musse Hosp, Dept Pneumol, Toulon, France

[17] Georges Pompidou European Hosp, Dept Biol, Paris, France

[18] Aix Marseille Univ, Multidisciplinary Oncol & Therapeut Innovat Dept, INSERM, CNRS,CRCM,APHM, Marseille, France

[19] Univ Hosp, Chest Dis & thorac oncol Dept, Besancon, France

[20] Bourgogne Franche Comte Univ, INSERM UMR 1098, Besancon, France

[21] Hop Bichat Claude Bernard, Serv Chirurg thorac, 46 rue Henri Huchard, F-75018 Paris, France

来源：

CLINICAL LUNG CANCER | 2023年 / 24卷 / 01期

关键词：

NSCLC; Surgery; Molecular profile; Prognosis; Stage I-II disease; GROWTH-FACTOR RECEPTOR; GEFITINIB; KRAS; INHIBITORS;

D O I：

10.1016/j.cllc.2022.08.013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Molecular profile of localized non-small cell lung cancer has not been reported in Western Europe. In the nation-wide Biomarker France study, EGFR mutations were found in 12.9% of resected stage I-II NSCLC, associated with 5-year DFS of 65% and 5-year OS of 75%. No difference was found between EGFR-mutant and EGFR-wt tumors regarding recurrence site, disease-free survival, and overall survival.Introduction: Molecular profile of resected stage I-II non-small cell lung cancer (NSCLC) would help refine prognosis and personalize induction or adjuvant strategies. We sought to report the molecular profile of resected stage I-II NSCLC and analyzed the impact of epidermal growth factor receptor (EGFR) mutations on outcomes in a Western population. Patients and Methods: Surgical cases were identified from Biomarkers France study, a nationwide prospective study including NSCLC patients screened for EGFR, HER2, KRAS, BRAF, PIK3CA, ALK alterations from 2012 to 2013. Among surgical patients, clinical charts of the largest centers were reviewed in order to analyze the prognostic impact of EGFR mutations. Results: In the BMF database (n = 17.636), surgical patients (n = 854) were characterized by a higher propor-tion of EGFR mutations than nonsurgical patients (12.9% vs. 10.2%, P = .025), while the other molecular alterations did not differ. The proportion of EGFR mutations was 27% in women undergoing surgery. In the study group (n = 293; EGFR wild type, n = 235; usual mutation, n = 50; rare mutation, n = 8), after a median follow-up of 67 months, 215 patients (74.4%) had not relapsed. No difference was found between EGFR-mutant and EGFR-wt tumors regarding recurrence site, disease-free survival, and overall survival. The 5-year disease-free survival and overall survival after surgical resection of stage I-II EGFR-mutated tumors were 65% and 75%, respectively. Conclusion: In resected stage I to II NSCLC, EGFR mutations were found in 12.9% of cases, associated with a 5-year overall survival of 75%, with no impact on recurrence site, disease-free survival, and overall survival.

引用

页码：1 / 10

页数：10

共 26 条

[1] Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) [J].

Barlesi, Fabrice ;

Mazieres, Julien ;

Merlio, Jean-Philippe ;

Debieuvre, Didier ;

Mosser, Jean ;

Lena, Herve ;

Ouafik, L'Houcine ;

Besse, Benjamin ;

Rouquette, Isabelle ;

Westeel, Virginie ;

Escande, Fabienne ;

Monnet, Isabelle ;

Lemoine, Antoinette ;

Veillon, Remi ;

Blons, Helene ;

Audigier-Valette, Clarisse ;

Bringuier, Pierre-Paul ;

Lamy, Regine ;

Beau-Faller, Michele ;

Pujol, Jean-Louis ;

Sabourin, Jean-Christophe ;

Penault-Llorca, Frederique ;

Denis, Marc G. ;

Lantuejoul, Sylvie ;

Morin, Franck ;

Quan Tran ;

Missy, Pascale ;

Langlais, Alexandra ;

Milleron, Bernard ;

Cadranel, Jacques ;

Soria, Jean-Charles ;

Zalcman, Gerard .

LANCET, 2016, 387 (10026) :1415-1426

[2] A Multicenter Blinded Study Evaluating EGFR and KRAS Mutation Testing Methods in the Clinical Non-Small Cell Lung Cancer Setting-IFCT/ERMETIC2 Project Part 1 Comparison of Testing Methods in 20 French Molecular Genetic National Cancer Institute Platforms [J].

Beau-Faller, Michele ;

Blons, Helene ;

Domerg, Caroline ;

Gajda, Dorota ;

Richard, Nicolas ;

Escande, Fabienne ;

Solassol, Jerome ;

Denis, Marc G. ;

Cayre, Anne ;

Nanni-Metellus, Isabelle ;

Olschwang, Sylviane ;

Lizard, Sarab ;

Piard, Fabienne ;

Pretet, Jean-Luc ;

de Fraipont, Florence ;

Bieche, Ivan ;

de Cremoux, Patricia ;

Rouquette, Isabelle ;

Bringuier, Pierre-Paul ;

Mosser, Jean ;

Legrain, Michele ;

Voegeli, Anne-Claire ;

Saulnier, Patrick ;

Morin, Franck ;

Pignon, Jean-Pierre ;

Zalcman, Gerard ;

Cadranel, Jacques .

JOURNAL OF MOLECULAR DIAGNOSTICS, 2014, 16 (01) :45-55

[3] Cross-Validation Study for Epidermal Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded Non-small Cell Lung Carcinoma Samples A Total of 5550 Exons Sequenced by 15 Molecular French Laboratories (Evaluation of the EGFR Mutation Status for the Administration of EGFR-TKIs in Non-Small Cell Lung Carcinoma [ERMETIC] Project-Part 1) [J].

Beau-Faller, Michele ;

Degeorges, Armelle ;

Rolland, Estelle ;

Mounawar, Mounia ;

Antoine, Martine ;

Poulot, Virginie ;

Mauguen, Audrey ;

Barbu, Veronique ;

Coulet, Florence ;

Pretet, Jean-Luc ;

Bieche, Ivan ;

Blons, Helene ;

Boyer, Jean-Christophe ;

Buisine, Marie-Pierre ;

de Fraipont, Florence ;

Lizard, Sarab ;

Olschwang, Sylviane ;

Saulnier, Patrick ;

Prunier-Mirebeau, Delphine ;

Richard, Nicolas ;

Danel, Claire ;

Brambilla, Elisabeth ;

Chouaid, Christos ;

Zalcman, Gerard ;

Hainaut, Pierre ;

Michiels, Stefan ;

Cadranel, Jacques .

JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) :1006-1015

[4] Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials [J].

Bell, DW ;

Lynch, TJ ;

Haserlat, SM ;

Harris, PL ;

Okimoto, RA ;

Brannigan, BW ;

Sgroi, DC ;

Muir, B ;

Riemenschneider, MJ ;

Iacona, RB ;

Krebs, AD ;

Johnson, DH ;

Giaccone, G ;

Herbst, RS ;

Manegold, C ;

Fukuoka, M ;

Kris, MG ;

Baselga, J ;

Ochs, JS ;

Haber, DA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) :8081-8092

[5] Performance and Cost Efficiency of KRAS Mutation Testing for Metastatic Colorectal Cancer in Routine Diagnosis: The MOKAECM Study, a Nationwide Experience [J].

Blons, Helene ;

Rouleau, Etienne ;

Charrier, Nathanael ;

Chatellier, Gilles ;

Cote, Jean-Francois ;

Pages, Jean-Christophe ;

de Fraipont, Florence ;

Boyer, Jean-Christophe ;

Merlio, Jean Philippe ;

Morel, Alain ;

Gorisse, Marie-Claude ;

de Cremoux, Patricia ;

Leroy, Karen ;

Milano, Gerard ;

Ouafik, L'Houcine ;

Merlin, Jean-Louis ;

Le Corre, Delphine ;

Aucouturier, Pascaline ;

Sabourin, Jean-Christophe ;

Nowak, Frederique ;

Frebourg, Thierry ;

Emile, Jean-Francois ;

Durand-Zaleski, Isabelle ;

Laurent-Puig, Pierre .

PLOS ONE, 2013, 8 (07)

[6] Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib [J].

Eberhard, DA ;

Johnson, BE ;

Amler, LC ;

Goddard, AD ;

Heldens, SL ;

Herbst, RS ;

Ince, WL ;

Jänne, PA ;

Januario, T ;

Johnson, DH ;

Klein, P ;

Miller, VA ;

Ostland, MA ;

Ramies, DA ;

Sebisanovic, D ;

Stinson, JA ;

Zhang, YR ;

Seshagiri, S ;

Hillan, KJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5900-5909

[7] The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non-Small Cell Lung Cancer [J].

Edwards, John G. ;

Chansky, Kari ;

Van Schil, Paul ;

Nicholson, Andrew G. ;

Boubia, Souheil ;

Brambilla, Elisabeth ;

Donington, Jessica ;

Galateau-Salle, Francoise ;

Hoffmann, Hans ;

Infante, Maurizio ;

Marino, Mirella ;

Marom, Edith M. ;

Nakajima, Jun ;

Ostrowski, Marcin ;

Travis, William D. ;

Tsao, Ming-Sound ;

Yatabe, Yasushi ;

Giroux, Dorothy J. ;

Shemanski, Lynn ;

Crowley, John ;

Krasnik, Marc ;

Asamura, Hisao ;

Rami-Porta, Ramon .

JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (03) :344-359

[8] The IASLC lung cancer staging project: Proposals for the revision of he TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours [J].

Goldstraw, Peter ;

Crowley, John ;

Chansky, Kari ;

Giroux, Dorothy J. ;

Groome, Patti A. ;

Rami-Porta, Ramon ;

Postmus, Pieter E. ;

Rusch, Valerie ;

Sobin, Leslie .

JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) :706-714

[9] Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial [J].

He, Jianxing ;

Su, Chunxia ;

Liang, Wenhua ;

Xu, Shidong ;

Wu, Lin ;

Fu, Xiangning ;

Zhang, Xiaodong ;

Ge, Di ;

Chen, Qun ;

Mao, Weimin ;

Xu, Lin ;

Chen, Chun ;

Hu, Bing ;

Shao, Guoguang ;

Hu, Jian ;

Zhao, Jian ;

Liu, Xiaoqing ;

Liu, Zhidong ;

Wang, Zheng ;

Xiao, Zemin ;

Gong, Taiqian ;

Lin, Wen ;

Li, Xingya ;

Ye, Feng ;

Liu, Yang ;

Ma, Haitao ;

Huang, Yunchao ;

Zhou, Jianying ;

Wang, Zhonglin ;

Fu, Junke ;

Ding, Lieming ;

Mao, Li ;

Zhou, Caicun .

LANCET RESPIRATORY MEDICINE, 2021, 9 (09) :1021-1029

[10] Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial [J].

Kelly, Karen ;

Altorki, Nasser K. ;

Eberhardt, Wilfried E. E. ;

O'Brien, Mary E. R. ;

Spigel, David R. ;

Crino, Lucio ;

Tsai, Chun-Ming ;

Kim, Joo-Hang ;

Cho, Eun Kyung ;

Hoffman, Philip C. ;

Orlov, Sergey V. ;

Serwatowski, Piotr ;

Wang, Jiuzhou ;

Foley, Margaret A. ;

Horan, Julie D. ;

Shepherd, Frances A. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) :4007-+

← 1 2 3 →